公开(公告)号：WO2008011100A3

公开(公告)日：2008-04-10

申请号：PCT/US2007016369

申请日：2007-07-19

Applicant: BAKER MED RES INST ,  KAYE DAVID MARTIN ,  BYRNE MELISSA JANE ,  SHAPLAND JAMES EDWARD ,  DOAN TUAN ,  BILNEY ADAM LUCAS

Inventor： KAYE DAVID MARTIN ,  BYRNE MELISSA JANE ,  SHAPLAND JAMES EDWARD ,  DOAN TUAN ,  BILNEY ADAM LUCAS

IPC: A61F2/958 ,  A61M1/36

CPC classification number: A61M25/10 ,  A61B17/22 ,  A61B2017/22082 ,  A61M1/3653 ,  A61M1/3659 ,  A61M1/3667 ,  A61M25/104 ,  A61M2025/0031 ,  A61M2027/004

Abstract: A method for treating an occlusion in a coronary artery of a patient includes percutaneously advancing an occlusion treatment tool (such as an angioplasty balloon or stent delivery device) through the vasculature of the patient and into a coronary artery to a site of the occlusion. Following the treatment of the occlusion, a therapeutic agent is admitted into the first coronary artery. The therapeutic agent is selected to treat microvasculature obstructions at a target cardiac tissue site distal to the site of the occlusion.

Abstract translation: 治疗患者冠状动脉闭塞的方法包括将闭塞治疗工具（例如血管成形术气囊或支架输送装置）经皮肤推进穿过患者的脉管系统并进入冠状动脉至闭塞部位。 治疗闭塞后，治疗剂进入第一冠状动脉。 选择治疗剂以治疗闭塞部位远侧的目标心脏组织部位处的微血管阻塞。

公开(公告)号：WO2008011100A2

公开(公告)日：2008-01-24

申请号：PCT/US2007/016369

申请日：2007-07-19

Applicant: THE BAKER MEDICAL RESEARCH INSTITUTE ,  KAYE, David, Martin ,  BYRNE, Melissa, Jane ,  SHAPLAND, James, Edward ,  DOAN, Tuan ,  BILNEY, Adam, Lucas

Inventor： KAYE, David, Martin ,  BYRNE, Melissa, Jane ,  SHAPLAND, James, Edward ,  DOAN, Tuan ,  BILNEY, Adam, Lucas

IPC: A61K31/00

CPC classification number: A61M25/10 ,  A61B17/22 ,  A61B2017/22082 ,  A61M1/3653 ,  A61M1/3659 ,  A61M1/3667 ,  A61M25/104 ,  A61M2025/0031 ,  A61M2027/004

Abstract: A method for treating an occlusion in a coronary artery of a patient includes percutaneously advancing an occlusion treatment tool (such as an angioplasty balloon or stent delivery device) through the vasculature of the patient and into a coronary artery to a site of the occlusion. Following the treatment of the occlusion, a therapeutic agent is admitted into the first coronary artery. The therapeutic agent is selected to treat microvasculature obstructions at a target cardiac tissue site distal to the site of the occlusion.

Abstract translation: 用于治疗患者冠状动脉闭塞的方法包括通过患者的脉管系统经皮推进闭塞治疗工具（例如血管成形术球囊或支架输送装置）并进入冠状动脉至闭塞部位。 治疗闭塞后，治疗剂进入第一冠状动脉。 治疗剂被选择用于治疗位于闭塞部位远端的靶心脏组织部位的微血管阻塞物。